-
摘要: 免疫性血小板减少症是临床上最常见的出血性疾病之一，部分患者因合并症有手术治疗的需要。为减少不良反应发生、保障患者安全，本文通过归纳总结国内外指南共识、临床研究及病例报道，分别针对免疫性血小板减少症患者围手术期的术前评估、治疗及术后管理进行介绍，并提出相应的建议。Abstract: Immune thrombocytopenia(ITP) is a common clinical disorder with a variably increased risk of bleeding. Some ITP patients have complications and need surgery. From summarizing related guidelines, consensus, clinical trials and case reports, we make recommendation on preoperative assessment, perioperative treatment and postoperative management for ITP patients, aimed at minimizing adverse events and ensure safety.
-
Key words:
- immune thrombocytopenia /
- perioperative period /
- evaluation /
- treatment
-
-
表 1 成人ITP出血评分系统
分值 年龄/岁 皮下出血(瘀点/瘀斑/血肿) 黏膜出血(鼻腔/齿龈/口腔血疱/结膜) 深部器官出血 ≥65 ≥75 头面部 其他部位 偶发、可自止 多发、难止 伴贫血 内脏(肺、胃肠道、泌尿生殖系统) 中枢神经系统 无贫血 伴贫血 危及生命 1 √ √ 2 √ √ √ 3 √ √ 5 √ √ 8 √ √ 
下载: 导出CSV
-
[1] 中华医学会血液学分会血栓与止血学组. 成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版)[J]. 中华血液学杂志, 2020, 41(8): 617-623. https://www.cnki.com.cn/Article/CJFDTOTAL-LCLZ202106026.htm
[2] Bussel J, Cooper N, Boccia R, et al. Immune thrombocytopenia[J]. Expert Rev Hematol, 2021, 14(11): 1013-1025. doi: 10.1080/17474086.2021.1995347
[3] Estcourt LJ, Birchall J, Allard S, et al. Guidelines for the use of platelet transfusions[J]. Br J Haematol, 2017, 176(3): 365-394. doi: 10.1111/bjh.14423
[4] Rodeghiero F, Michel M, Gernsheimer T, et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group[J]. Blood, 2013, 121(14): 2596-2606. doi: 10.1182/blood-2012-07-442392
[5] Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia[J]. Blood Adv, 2019, 3(22): 3780-3817. doi: 10.1182/bloodadvances.2019000812
[6] Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia[J]. Blood, 2010, 115(2): 168-186. doi: 10.1182/blood-2009-06-225565
[7] Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia[J]. Blood Adv, 2019, 3(23): 3829-3866. doi: 10.1182/bloodadvances.2019000966
[8] Guo S, Dipietro LA. Factors affecting wound healing[J]. J Dent Res, 2010, 89(3): 219-229. doi: 10.1177/0022034509359125
[9] Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group[J]. Blood, 2009, 113(11): 2386-2393. doi: 10.1182/blood-2008-07-162503
[10] Neunert CE. Management of newly diagnosed immune thrombocytopenia: can we change outcomes?[J]. Blood, 2017, 1(24): 2295-2301. Erratum in: Blood Adv, 2018, 2(15): 1817.
[11] Mithoowani S, Gregory-Miller K, Goy J, et al. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis[J]. Lancet Haematol, 2016, 3(10): e489-e496. doi: 10.1016/S2352-3026(16)30109-0
[12] 中华医学会血液学分会血栓与止血学组. 促血小板生成药物临床应用管理中国专家共识(2023年版)[J]. 中华血液学杂志, 2023, 44(7): 535-542.
[13] Al-Samkari H, Marshall AL, Goodarzi K, et al. Romiplostim for the management of perioperative thrombocytopenia[J]. Br J Haematol, 2018, 182(1): 106-113. doi: 10.1111/bjh.15280
[14] Marshall AL, Goodarzi K, Kuter DJ. Romiplostim in the management of the thrombocytopenic surgical patient[J]. Transfusion, 2015, 55(10): 2505-2510. doi: 10.1111/trf.13181
[15] Arnold DM, Heddle NM, Cook RJ, et al. Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial[J]. Lancet Haematol, 2020, 7(9): e640-e648. doi: 10.1016/S2352-3026(20)30227-1
[16] Kaur MN, Arnold DM, Heddle NM, et al. Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia[J]. Blood Adv, 2022, 6(3): 785-792. doi: 10.1182/bloodadvances.2021005627
[17] Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia[J]. Br J Haematol, 2018, 183(3): 479-490. doi: 10.1111/bjh.15573
[18] Chang CC, Chang HC, Wu CH, et al. Adverse postoperative outcomes in surgical patients with immune thrombocytopenia[J]. Br J Surg, 2013, 100(5): 684-692. doi: 10.1002/bjs.9065
[19] Kojouri K, Vesely SK, Terrell DR, et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications[J]. Blood, 2004, 104(9): 2623-2634. doi: 10.1182/blood-2004-03-1168
[20] Enger C, Bennett D, Forssen U, et al. Comorbidities in patients with persistent or chronic immune thrombocytopenia[J]. Int J Hematol, 2010, 92(2): 289-295. doi: 10.1007/s12185-010-0636-3
[21] Cayco AV, Perazella MA, Hayslett JP. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature[J]. J Am Soc Nephrol, 1997, 8(11): 1788-1794. doi: 10.1681/ASN.V8111788
[22] Skeith L, Baumann Kreuziger L, Crowther MA, et al. A practical approach to evaluating postoperative thrombocytopenia[J]. Blood Adv, 2020, 4(4): 776-783. doi: 10.1182/bloodadvances.2019001414
[23] Nørgaard M, Jensen AO, Engebjerg MC, et al. Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study[J]. Blood, 2011, 117(13): 3514-3520. doi: 10.1182/blood-2010-10-312819
[24] Cokkinos DD, Spanou E, Giannou S, et al. Pulmonary nocardiosis in a patient with idiopathic thrombocytopenic purpura[J]. J Infect, 2006, 52(2): e41-e43. doi: 10.1016/j.jinf.2005.05.016
[25] Thomsen RW, Schoonen WM, Farkas DK, et al. Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study[J]. Ann Intern Med, 2009, 151(8): 546-555. doi: 10.7326/0003-4819-151-8-200910200-00008
[26] 中华医学会血液学分会血栓与止血学组. 原发免疫性血小板减少症合并血栓/栓塞诊断与防治中国专家共识(2023年版)[J]. 中华血液学杂志, 2023, 44(1): 6-11.
-
| 引用本文: |
李俊颖, 郭涛. 免疫性血小板减少症患者围手术期的评估与治疗[J]. 临床血液学杂志, 2024, 37(1): 10-13. doi: 10.13201/j.issn.1004-2806.2024.01.003
|
| Citation: |
LI Junying, GUO Tao. Perioperative evaluation and treatment of immune thrombocytopenia[J]. J Clin Hematol, 2024, 37(1): 10-13. doi: 10.13201/j.issn.1004-2806.2024.01.003
|